Dermira (Dermira) Risk Assessment

View and export this data going back to 2014. Start your Free Trial

What is Dermira Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Dermira is: No Data: Cannot be evaluated.

Competitive Comparison of Dermira's Risk Assessment

For the Biotechnology subindustry, Dermira's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dermira's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dermira's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Dermira's Risk Assessment falls into.

Dermira (NAS:DERM) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Dermira Risk Assessment Related Terms

Thank you for viewing the detailed overview of Dermira's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Dermira (Dermira) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dermira Inc (NAS:DERM) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

275 Middlefield Road, Suite 150, Menlo Park, CA, USA, 94025

Website

http://www.dermira.com

Dermira Inc is a biopharmaceutical company focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States.The company's late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne.

Executives

Halley E Gilbert	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
William R Ringo	director
Fred B Craves	director	750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
David E Cohen	director	3160 PORTER DRIVE, PALO ALTO CA 94304
Thomas G Wiggans	director, officer: CEO & Chairman of the Board
Jason Raleigh Nunn	director	1119 ST. PAUL STREET, BALTIMORE MD 21202
Andrew Guggenhime	officer: CFO	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Lori Lyons-williams	officer: Chief Commercial Officer	C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Kathleen Sebelius	director	C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Eugene A Bauer	director, officer: Chief Medical Officer	C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Lilly Eli & Co	10 percent owner	LILLY CORPORATE CENTER, DROP CODE 1094, INDIANAPOLIS IN 46285
Mark Mcdade	director	C/O PROTINE DESIGN LAB, 7442 NORTH MARCER WAY, MERCER ISLAND WA 98040
Matthew K Fust	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Canaan Partners Viii Llc	director	285 RIVERSIDE AVE, STE 250, WESTPORT CT 06880
Canaan Viii Lp	director	2765 SAND HILL RD, MENLO PARK CA 94025